BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Carb-X - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://carb-x.org
X-WR-CALDESC:Events for Carb-X
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201130
DTEND;VALUE=DATE:20201204
DTSTAMP:20260403T183133
CREATED:20200924T152007Z
LAST-MODIFIED:20200924T152007Z
UID:4410-1606694400-1607039999@carb-x.org
SUMMARY:World Vaccine and Immunotherapy Congress West Coast 2020
DESCRIPTION:In December 2019 SARS-CoV-2 the cause of COVID-19\, was responsible for thousands of deaths in Wuhan\, China. By March 11\, 2020\, WHO declared COVID-19 as a worldwide pandemic.The single most effective way to tackle this pandemic is a working vaccine\, which is why Vaccine Congress West Coast is bringing together experts who have been working tirelessly to make this happen\, in a safe\, virtual environment. This is the most important meeting you will be part of. Now more than ever\, we need everyone’s contribution to solve this global problem. \nCome together and join us VIRTUALLY to identify the urgent priorities for research. To mobilize\, coordinate and align funding to enable the research needed to tackle this crisis and stop the outbreak\, and commit with our experts how you can learn mechanisms for continuing scientific interactions and collaborations\, now and beyond the congress. \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/world-vaccine-and-immunotherapy-congress-west-coast-2020/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201202
DTEND;VALUE=DATE:20201203
DTSTAMP:20260403T183133
CREATED:20201202T230539Z
LAST-MODIFIED:20201202T230539Z
UID:4663-1606867200-1606953599@carb-x.org
SUMMARY:Global AMR Hub Virtual Conference
DESCRIPTION:Translating AMR R&D mapping into policy and action.\nThe Global AMR R&D Hub\, through its Dynamic Dashboard\, is the global knowledge centre for AMR R&D. The Dynamic Dashboard captures and presents: AMR R&D investments from across the globe and One Health sectors; what new antibacterials are in the pipeline; and what is being done to overcome the challenges hindering the development of\, and access to and stewardship of\, priority antibacterials. The important next step for the Global AMR R&D Hub is to take the repository of information\, that is the Dynamic Dashboard\, and translate this into policy and action. \nThis virtual conference is the start of this next important step for the Global AMR R&D Hub. The virtual conference begins discussions to inform how the Global AMR R&D Hub\, using its Dynamic Dashboard\, can support the AMR R&D needs in the different regions and countries\, by highlighting gaps that need to be filled and helping to identify collaboration or partnership opportunities. The three sessions of the conference focus on three different areas to do this: \nCARB-X participants include Kevin Outterson\, Executive Director\, and Erin Duffy\, Chief of Research & Development. \nClick here to learn more.
URL:https://carb-x.org/event/global-amr-hub-virtual-conference/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201202
DTEND;VALUE=DATE:20201205
DTSTAMP:20260403T183133
CREATED:20201202T232133Z
LAST-MODIFIED:20201202T232133Z
UID:4664-1606867200-1607126399@carb-x.org
SUMMARY:Infectious Diseases Virtual Partnering
DESCRIPTION:Infectious diseases have always impacted human history\, but in the past 50 years we have managed to control or eliminate some infectious diseases through improved hygiene\, vaccination\, antimicrobials\, advances in medicine and public health policies. However\, the current pandemic is a reminder that we need to continue to pursue our efforts to control these pathogens\, especially with intercontinental travel and increased mobility of people and animals. \nTo manage infectious diseases\, we use tools such as vaccines\, antibiotics\, antivirals\, diagnostic tools and biomarkers. But today there are many infectious diseases for which we do not have satisfactory preventive tools or treatment options\, such as SARS-CoV-2\, Zika virus\, Ebola virus\, multidrug resistant bacteria\, HIV\, Malaria. To develop these future tools\, collaboration is essential\, either for sourcing assets in the vaccine\, antiviral or antibiotic space\, or for finding research tools to help in screening\, in-vivo modelling\, clinical trials and diagnostics and biomarkers. \nIt is in this context that we are organising the Infectious Diseases Virtual Partnering event\, focusing on diseases caused by organisms such as bacteria\, viruses\, fungi\, or parasites. With current travel restrictions\, this virtual event will help you to find the right business partner to pursue your objectives.  This event will leverage Inova and Biotechnology Innovation Organization (BIO)’s biopharma industry expertise\, leading digital networking platform and years of experience organizing partnering events to connect scientific and business communities for the benefit of patients worldwide. \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/infectious-diseases-virtual-partnering/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20201203T030000
DTEND;TZID=America/New_York:20201203T043000
DTSTAMP:20260403T183133
CREATED:20201112T205113Z
LAST-MODIFIED:20201112T205113Z
UID:4572-1606964400-1606969800@carb-x.org
SUMMARY:Evidence to Action Webinar: Advancing the Antimicrobial Resistance agenda during a pandemic
DESCRIPTION:How can efforts to implement Antimicrobial Resistance National Action Plans still progress despite the COVID-19 pandemic? \nThere is no doubt COVID-19 currently represents the most obvious and urgent issue for global health security and the world is rightfully focused on tackling this pandemic. However\, the challenges posed by COVID-19 are only a foretaste of what antimicrobial resistance (AMR) can mean to the world without appropriate interventions. AMR\, the silent pandemic\, can impact many of the global health achievements of past decades and jeopardize efforts to deliver on many of the Sustainable Development Goals. \nThis webinar provides an opportunity to gain insights into current efforts to continuously move forward the agenda of combatting AMR amidst the COVID-19 pandemic. Key experts and opinion leaders will share their strategic reflections and insights focusing on what evidence and data are currently available and how best to leverage them into action to tackle AMR\, especially in low- and middle-income countries. \nThis event is co-hosted by the International Vaccine Institute (IVI)\, the International Centre for Antimicrobial Resistance Solutions (ICARS) and the Embassy of Denmark in Korea. Speakers from IVI\, ICARS\, WHO and the UK will lead the panel discussion. Please join the conversation and ask questions to our panel. \nTo learn more\, click here. \nTo register\, click here.\nPlease note that registration is required\, and a link to webinar will be shared in advance to registered attendees \nDecember 3\, 2020\n9:00-10:30 AM (CET); 5:00-6:30 PM (KST); 3:00-4:30 AM (EST)
URL:https://carb-x.org/event/evidence-to-action-webinar-advancing-the-antimicrobial-resistance-agenda-during-a-pandemic/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201207
DTEND;VALUE=DATE:20201211
DTSTAMP:20260403T183133
CREATED:20201029T160029Z
LAST-MODIFIED:20201128T210915Z
UID:4523-1607299200-1607644799@carb-x.org
SUMMARY:Milken Institute Future of Health Summit
DESCRIPTION:The Milken Institute Future of Health Summit convenes the best minds in the world to confront the most significant health challenges by matching human\, financial\, scientific\, and educational resources with innovative and impactful ideas. The Summit will focus on the converging crises of public health\, economic insecurity\, and social injustice. COVID-19 has exposed weaknesses across our health systems\, particularly in the treatment of our most vulnerable communities\, where access to affordable and quality health care has never been more vital. \nParticipants include Kevin Outterson\, Executive Director of CARB-X\, who will be moderating a session entitled “Are Resistant Infections the Next Pandemic? New Antibiotics Need New Incentives” on Tuesday\, December 8th from 12:00pm – 1:00pm EST. \nAre Resistant Infections the Next Pandemic? New Antibiotics Need New Incentives: Antibiotic treatment in COVID-19 patients is driving antimicrobial resistance (AMR) as secondary infections emerge. While large pharmaceutical companies have retreated from antibiotic development\, smaller enterprises have compensated with innovative therapies to ensure an arsenal of anti-infective drugs. But numerous recent bankruptcies show that times are tough even for companies with newly approved antibiotics. Several large pharmaceutical companies recently joined in launching the billion-dollar Antimicrobial Action Fund for antibiotic development. This welcome investment buys time to right the market\, but it is clear that a pull incentive is needed to drive the market. What are the lessons to learn from the UK NHS NICE subscription-model pilot? Is a pull incentive enough to attract private investment to antimicrobials? How can we develop a sustainable market for antibiotics so that drug-resistant infections do not become the next pandemic? \nSpeakers Include: \n\nMichael Boyle\nPresident and CEO\, Cystic Fibrosis Foundation\nNick Crabb\nProgramme Director\, Scientific Affairs\, National Institute for Health and Care Excellence (NICE)\nSally Davies\nUK Special Envoy on Antimicrobial Resistance\, UK Government\nOdysseas Kostas\nPartner and Senior Managing Director\, Sarissa Capital\n\nTo learn more\, click here.\nTo view the program\, click here.
URL:https://carb-x.org/event/milken-institute-future-of-health-summit/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201207
DTEND;VALUE=DATE:20201212
DTSTAMP:20260403T183133
CREATED:20201202T232424Z
LAST-MODIFIED:20201202T232424Z
UID:4665-1607299200-1607731199@carb-x.org
SUMMARY:2020 ASM Conference on Next-Generation Sequencing
DESCRIPTION:Join us at the virtual 2020 ASM Conference on Next-Generation Sequencing\, taking place Dec. 7-11\, 2020\, and get comprehensive guidance with up-to-date examples in the use of NGS technology for applied results in the traceability and clustering of microbial pathogens associated with food safety\, clinical infection\, environmental contamination and other potential sources of disease outbreaks. You’ll walk away with access to the available resources and direction you need relating to bioinformatics and epidemiology. \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/2020-asm-conference-on-next-generation-sequencing/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201208
DTEND;VALUE=DATE:20201211
DTSTAMP:20260403T183133
CREATED:20201112T203844Z
LAST-MODIFIED:20220803T215834Z
UID:4573-1607385600-1607644799@carb-x.org
SUMMARY:BLUE KNIGHT™ Symposium
DESCRIPTION:CARB-X participants include Erin Duffy\, Chief of R&D. \nJohnson & Johnson Innovation – JLABS is collaborating with the Biomedical Advanced Research and Development Authority (BARDA)\, a component of the Administration for Strategic Preparedness and Response in the U.S. Department of Health and Human Services\, to form Blue Knight. This collaboration aims to stimulate innovation and incubation of technologies that improve health security and response through companies focused on public health threats and emerging infectious diseases. Find out more about BARDA and its mission at www.PHE.gov/BARDA. \nIn seeking to combat emerging infectious diseases and other 21st century health threats\, the path to better prepared\, protected\, and healthy individuals\, families\, and communities could rely on unlocking the collective power of the global community. BLUE KNIGHT™ seeks to answer this call. \nOn December 8-10\, Johnson & Johnson Innovation – JLABS and BARDA will virtually convene the emerging Blue Knight community of thought leaders\, innovators and entrepreneurs for a three-day symposium\, including interactive sessions focused on key areas of interest in infectious disease\, public health\, and company acceleration. Sessions will explore high priority areas of interest for scientific and technological innovation aimed for improving our preparedness and response to emerging health security threats. \nTo learn more\, click here.\nTo register\, click here.
URL:https://carb-x.org/event/blue-knight-symposium/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
END:VCALENDAR